Provided by Tiger Trade Technology Pte. Ltd.

Sunshine Biopharma Inc.

0.9623
-0.0042-0.43%
Post-market: 0.9501-0.0122-1.27%18:07 EDT
Volume:32.24K
Turnover:30.88K
Market Cap:4.72M
PE:-0.67
High:0.9646
Open:0.9500
Low:0.9500
Close:0.9665
52wk High:2.43
52wk Low:0.9500
Shares:4.91M
Float Shares:4.90M
Volume Ratio:1.21
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4400
EPS(LYR):-1.4374
ROE:-25.68%
ROA:-9.23%
PB:0.21
PE(LYR):-0.67

Loading ...

Sunshine Biopharma expects to reduce expenses by $2M-$3M in 2026

TIPRANKS
·
Apr 06

Sunshine Biopharma FY25 net loss widens 16.39% to $5.98 million

Reuters
·
Apr 03

Sunshine Biopharma delays annual report filing, expects to submit within 15 days

Reuters
·
Apr 01

Sunshine Biopharma Inc expected to post a loss of 27 cents a share - Earnings Preview

Reuters
·
Mar 28

Sunshine Biopharma Files Information Statement on Up to 1-for-10 Reverse Stock Split Authorization

Reuters
·
Mar 03

Sunshine Biopharma Files Draft Information Statement on Authorized Up-to-1-for-10 Reverse Stock Split Amendment

Reuters
·
Feb 21

Sunshine Biopharma COO Abderrazzak Merzouki Resigns

Reuters
·
Feb 06

Sunshine Biopharma Inc. Held Annual Shareholder Meeting

Reuters
·
Dec 13, 2025

Sunshine Biopharma Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
Nov 01, 2025

Sunshine Biopharma Secures Health Canada Approval to Market Domperidone

Reuters
·
Oct 29, 2025

Sunshine Biopharma Inc. Announces Date for 2025 Annual Shareholder Meeting

Reuters
·
Oct 24, 2025

Sunshine Biopharma announces commercial launch of doxycycline in Canada

TIPRANKS
·
Oct 20, 2025

Sunshine Biopharma’s Subsidiary Nora Pharma Launches Generic Pravastatin in Canada

Reuters
·
Oct 16, 2025

Sunshine Biopharma Inc. Announces Plans to Invest $5 Million in Bitcoin as Strategic Reserve Asset and May Increase Holdings as Funds Become Available

Reuters
·
Oct 14, 2025

Sunshine Biopharma Price Target Maintained With a $7.00/Share by Aegis Capital

Dow Jones
·
Oct 09, 2025